Behavioral and neuroendocrine assays for studying epilepsy-associated depression
Article first published online: 4 DEC 2013
Copyright © 2013 International League Against Epilepsy
Volume 54, Issue 12, page 2229, December 2013
How to Cite
Mazarati, A. (2013), Behavioral and neuroendocrine assays for studying epilepsy-associated depression. Epilepsia, 54: 2229. doi: 10.1111/epi.12397
- Issue published online: 4 DEC 2013
- Article first published online: 4 DEC 2013
To the Editors:
In their review, Brooks-Kayal et al. (2013) provided guidelines for using certain assays to study epilepsy-associated depression in the laboratory. These guidelines should be further refined so as to improve construct validity of models in question, throughput of preclinical trials, and the reliability of the findings.
- The authors propose the Porsolt test to study the inability of animals to cope with a stressful situation. The Porsolt test, which has been proposed for the use in inherently normal animals, consists of two steps. Step 1 is a 15-min swimming session purposed to induce depression; step 2 is the test proper, where animal's immobility is measured during the 5-min swimming trial. Models of major depression that involve animals with an inherently depressive phenotype, do not utilize the Porsolt test. Indeed, if the animal is already depressed, the first (i.e., “depressogenic”) swimming session is no longer required. Instead, a single 5-min trial is used, whereby “depressed” animals exhibitprolonged immobility vis-à-vis normal counterparts (Overstreet & Wegener, 2013). Epileptic rats show consistently increased immobility in the single-session test, that is they are depressed by the virtue of having epilepsy (Mazarati et al., 2008). Hence, the Porsolt test becomes unnecessary. The single-session test can be successfully applied for screening of effective therapies (Pineda et al., 2012). Not only would replacement of the Porsolt test with the single-session test reduce time, labor, and animals’ stress, but it may also improve the search for effective medications. Indeed, since psychostimulants reduce immobility in the Porsolt test, the specificity of the latter for selecting antidepressant drugs has been questioned (Petit-Demouliere et al., 2005).
- Given the strong subjective component associated with the interpretation of behavioral tests, having an additional, preferably objective, assay would be useful. The combined dexamethasone/corticotropin-releasing hormone (DEX/CRH) test can reveal the dysregulation of the stress hormone axis in depression (Watson et al., 2006). Indeed, in animals with chronic epilepsy, DEX/CRH test is consistently positive (Mazarati et al., 2009). The test is objective, inexpensive, and quick. In addition, the positive DEX/CRH test may serve as an independent disease biomarker, thereby addressing another important issue discussed by Brooks-Kayal et al. (2013).
The author declares no conflicts of interest. I confirm that I have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
- 2013) Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy. Epilepsia 54(Suppl. 4):44–60. , , , , , , , , , , , . (
- 2008) Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain 131:2071–2083. , , , , , . (
- 2009) Elevated plasma corticosterone level and depressive behavior in experimental temporal lobe epilepsy. Neurobiol Dis 34:457–461. , , , , , , , . (
- 2013) The flinders sensitive line rat model of depression – 25 years and still producing. Pharmacol Rev 65:143–155. , . (
- 2005) Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology 177:245–255. , , . (
- 2012) Interleukin-1beta causes fluoxetine resistance in an animal model of epilepsy-associated depression. Neurotherapeutics 9:477–485. , , , , , . (
- 2006) The dex/CRH test – is it better than the DST? Psychoneuroendocrinology 31:889–894. , , , , . (